Short‐term dual antiplatelet therapy in diabetic patients admitted for acute coronary syndrome treated with a new‐generation drug‐eluting stent
Abstract Background The optimal duration of dual antiplatelet therapy (DAPT) in patients with diabetes mellitus (DM) admitted with acute coronary syndrome (ACS) and treated with a drug‐eluting stent (DES) remains unclear. This is a prespecified sub‐study from the Randomised Evaluation of short‐term DUal antiplatelet therapy in patients with acute Coronary syndromE treated with a new generation DES (REDUCE) trial that was designed to determine the efficacy and safety of short‐term versus standard 12 months DAPT in diabetic patients with ACS undergoing percutaneous coronary intervention (PCI) using the COMBO stent. Methods In this study we included ACS diabetic patients enroled in the REDUCE trial treated with the COMBO stent and randomly assigned to either 3 or 12 months of DAPT. The primary study endpoint was the composite of all‐cause mortality, myocardial infarction (MI), stent thrombosis (ST), stroke, target vessel revascularisation (TVR), and bleeding complications at 12 and 24 months follow‐up. Results A total of 307 diabetic patients were included, of which 162 (52.8%) in the 3 months DAPT group and 145 (47.2%) in the 12 months DAPT group. Patient characteristics, PCI success, and number of stents used were similar in the 3 and 12 months DAPT groups. Occurrence of the primary study endpoint at 12 and 24 months follow‐up was comparable between the two groups (3.1 vs. 3.5%, p = 0.865, and 15.8 vs. 14.9%, p = 0.824, respectively). Moreover, the prevalence of the specific clinical outcome parameters (all‐cause mortality), MI, ST, stroke, TVR, and bleeding was similar in both study groups. Conclusions This sub‐analysis shows similar clinical outcomes following 3 months DAPT as compared to 12 months DAPT in diabetic patients undergoing PCI for ACS using the COMBO stent. These results suggest that, even in this particular subset of patients, short duration of DAPT might be considered safe. Future larger studies are warranted to provide more precise estimations in terms of safety and efficacy of short term DAPT in these high‐risk patients..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Diabetes/Metabolism Research and Reviews - 38(2022), 5 |
| Beteiligte Personen: |
Vranken, Nousjka P. A. [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2022 John Wiley & Sons Ltd. |
|---|
| Umfang: |
9 |
|---|
| doi: |
10.1002/dmrr.3530 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY004620771 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY004620771 | ||
| 003 | DE-627 | ||
| 005 | 20230307140414.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230214s2022 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1002/dmrr.3530 |2 doi | |
| 028 | 5 | 2 | |a DMRR_DMRR3530.xml |
| 035 | |a (DE-627)WLY004620771 | ||
| 035 | |a (WILEY)DMRR3530 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.77 |2 bkl | ||
| 084 | |a 44.89 |2 bkl | ||
| 100 | 1 | |a Vranken, Nousjka P. A. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Short‐term dual antiplatelet therapy in diabetic patients admitted for acute coronary syndrome treated with a new‐generation drug‐eluting stent |
| 264 | 1 | |c 2022 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2022 John Wiley & Sons Ltd. | ||
| 520 | |a Abstract Background The optimal duration of dual antiplatelet therapy (DAPT) in patients with diabetes mellitus (DM) admitted with acute coronary syndrome (ACS) and treated with a drug‐eluting stent (DES) remains unclear. This is a prespecified sub‐study from the Randomised Evaluation of short‐term DUal antiplatelet therapy in patients with acute Coronary syndromE treated with a new generation DES (REDUCE) trial that was designed to determine the efficacy and safety of short‐term versus standard 12 months DAPT in diabetic patients with ACS undergoing percutaneous coronary intervention (PCI) using the COMBO stent. Methods In this study we included ACS diabetic patients enroled in the REDUCE trial treated with the COMBO stent and randomly assigned to either 3 or 12 months of DAPT. The primary study endpoint was the composite of all‐cause mortality, myocardial infarction (MI), stent thrombosis (ST), stroke, target vessel revascularisation (TVR), and bleeding complications at 12 and 24 months follow‐up. Results A total of 307 diabetic patients were included, of which 162 (52.8%) in the 3 months DAPT group and 145 (47.2%) in the 12 months DAPT group. Patient characteristics, PCI success, and number of stents used were similar in the 3 and 12 months DAPT groups. Occurrence of the primary study endpoint at 12 and 24 months follow‐up was comparable between the two groups (3.1 vs. 3.5%, p = 0.865, and 15.8 vs. 14.9%, p = 0.824, respectively). Moreover, the prevalence of the specific clinical outcome parameters (all‐cause mortality), MI, ST, stroke, TVR, and bleeding was similar in both study groups. Conclusions This sub‐analysis shows similar clinical outcomes following 3 months DAPT as compared to 12 months DAPT in diabetic patients undergoing PCI for ACS using the COMBO stent. These results suggest that, even in this particular subset of patients, short duration of DAPT might be considered safe. Future larger studies are warranted to provide more precise estimations in terms of safety and efficacy of short term DAPT in these high‐risk patients. | ||
| 700 | 1 | |a Rasoul, Saman |4 aut | |
| 700 | 1 | |a Luijkx, Jasper J. P. |4 aut | |
| 700 | 1 | |a Pustjens, Tobias F. S. |4 aut | |
| 700 | 1 | |a Postma, Sonja |4 aut | |
| 700 | 1 | |a Kolkman, Evelien J. |4 aut | |
| 700 | 1 | |a Kedhi, Elvin |4 aut | |
| 700 | 1 | |a Rifqi, Sodiqur |4 aut | |
| 700 | 1 | |a Lee, Michael K. Y. |4 aut | |
| 700 | 1 | |a Ebelt, Henning |4 aut | |
| 700 | 1 | |a Merkely, Béla |4 aut | |
| 700 | 1 | |a Verdoia, Monica |4 aut | |
| 700 | 1 | |a Wojakowski, Wojtek |4 aut | |
| 700 | 1 | |a ’t Hof, Arnoud A. W. J. |4 aut | |
| 700 | 1 | |a Suryapranata, Harry |4 aut | |
| 700 | 1 | |a De Luca, Giuseppe |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes/Metabolism Research and Reviews |g 38(2022), 5 |w (DE-627)WLY004616901 |x 15207560 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2022 |g number:5 |g extent:9 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 936 | b | k | |a 44.77 |q ASE |
| 936 | b | k | |a 44.89 |q ASE |
| 951 | |a AR | ||
| 952 | |d 38 |j 2022 |e 5 |g 9 | ||